FDA OKs Novartis Tobi Podhaler

FDA Approves Novartis Tobi Podhaler for Certain Cystic Fibrosis Patients, the First and Only Dry Powder Inhaled Antibacterial in US TOBI Podhaler is indicated for certain cystic fibrosis patients with Pa and shortens treatment time by about 70% compared to nebulized TOBIA CF affects about 30,000 children and adults in the US with an average daily ... (more)

http://www.drugs.com/news/fda-oks-novartis-tobi-podhaler-43953.html?